Literature DB >> 28608167

Erratum to: JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.

Shubhasree Banerjee¹, Ann Biehl², Massimo Gadina³, Sarfaraz Hasni⁴, Daniella M Schwartz⁵.

Abstract

Entities: Disease Gene Species

Year: 2017 PMID： 28608167 PMCID： PMC7608299 DOI： 10.1007/s40265-017-0772-7

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

× No keyword cloud information.

Erratum to: Drugs (2017) 77:521–546 DOI 10.1007/s40265-017-0701-9

Page 539, Table 6 Janus Kinase Inhibitors in preclinical and early clinical development The first row/entry which currently reads: Should read:

Drug	Specificity	Clinical Status	Diseases
OP0155 [199]	JAK3	Preclinical	Rat adjuvant induced arthritis

Drug	Specificity	Clinical Status	Diseases
PF-06651600 [199]	JAK3	Phase 2 (ClinicalTrials.gov. NCT02969044, NCT02974868, NCT02958865)	Rheumatoid arthritis, alopecia areata, ulcerative colitis

2 in total

1. Non-toxic sulfur inhibits LPS-induced inflammation by regulating TLR-4 and JAK2/STAT3 through IL-6 signaling.

Authors: Dong Young Kang; Nipin Sp; Eun Seong Jo; Alexis Rugamba; Hyoung Do Kim; Il Ho Kim; Jong-Chan Park; Se Won Bae; Kyoung-Jin Jang; Young Mok Yang
Journal: Mol Med Rep Date: 2021-04-28 Impact factor: 2.952

2. Aligned electrospun poly(L-lactide) nanofibers facilitate wound healing by inhibiting macrophage M1 polarization via the JAK-STAT and NF-κB pathways.

Authors: Jian Xie; Xiaowei Wu; Shang Zheng; Kaili Lin; Jiansheng Su
Journal: J Nanobiotechnology Date: 2022-07-26 Impact factor: 9.429

2 in total